While ERBB2-targeting agents, including trastuzumab, deruxtecan, and ado-trastuzumab emtansine, are FDA-approved agents for the treatment of NSCLC patients who had received prior systemic therapy [29,30], MET amplification is currently included in the NCCN guideline as an emerging marker with available targeting agents including capmatinib, tepotinib, and crizotinib [31,32]. Here, MET is linked to non-small cell lung carcinoma.